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Available online 23 October 2010Considering the importance of a deeper understanding of the effect throughout life of opioid
analgesia at birth, our objectivewas to determinewhethermorphine administration in early life,
once a day for 7 days in 8-day-old rats, alters the nociceptive response over the short (P16),
medium (P30), and long term (P60) and to evaluate which system is involved in the altered
nociceptive response. The nociceptive responses were assessed by the formalin test, and the
behavior analyzed was the total time spent in biting and flicking of the formalin-injected
hindpaw, recorded during the first 5min (phase I) and from 15–30min (phase II). The morphine
group showed no change in nociceptive response at P16, but at P30 and P60, the nociceptive
response was increased in phase I, and in both phases, respectively. At P30 and P60, the animals
received a non-steroidal anti-inflammatory drug (indomethacin) or NMDA receptor antagonist
(ketamine) 30 min before the formalin test. The increase in the nociceptive response was
completely reversedbyketamine,andpartiallyby indomethacin.These results indicate thatearly
morphine exposure causes an increase in the nociceptive response in adult life. It is possible that
this lower nociception threshold is due to neuroadaptations in nociceptive circuits, such as the
glutamatergic system. Thus, this work demonstrates the importance of evaluating clinical
consequences related to early opioid administration and suggests a need for a novel design of
agents that may counteract opiate-induced neuroplastic changes.
© 2010 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Neonate rats1. Introduction
Opioid analgesics, such asmorphine, are themost effective and
frequently used substances for the relief of moderate to severemacologia, ICBS, UFRGS, R
. da Silva Torres).
the Elsevier OA license.pain. The use of these analgesics has increased in the Neonatal
Intensive Care Unit over the last few decades as a consequence
of changes and advances in the understanding, identification,
and treatment of pain in children (De Lima et al., 1996; El Sayedua Sarmento Leite, 500 sala 202, 90050-170 - Porto Alegre, RS, Brazil.
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Fig. 1 – Experimental design.
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in short- and long-term clinical outcomes of critically ill
neonates have necessitated the widespread use of opioid
drugs for analgesia and sedation (Suresh and Anand, 2001).
However, the consequences for the development of neurophys-
iological systems remain unknown.
The efficacy of morphine in reducing pain in neonatal
animals has already been demonstrated (Nandi and Fitzgerald,
2005; Rozisky et al., 2008). Although descending inhibitory
mechanisms are not completely formed until the third week
of life (Nandi and Fitzgerald, 2005), morphine and other opioid
receptor agonists are effective analgesics during the early
neonatal period due to the presence of spinal opioid receptors
frombirth (RahmanandDickenson, 1999). Inaprevious studyby
our group, using the tail-flick test (a measure of the pain
threshold at the spinal level), we observed that animals in the
second week of life showed an increased response to repeated
morphine administration without developing tolerance. How-
ever, at P80 rats showed greater morphine analgesia and a
classic tolerance effect. In addition, the animals that received
morphine from P8 until P14 displayed a longer duration of
morphine analgesia at the same age (P80) (Rozisky et al., 2008).
These results indicate that early morphine exposure lead to the
development of an altered opioid analgesic response that may
be expressed into adulthood. Although such effects are
described in the literature, the precise mechanisms that
underlie the long-term consequences of chronic opioid treat-
ment in the neonatal period have not been thoroughly
investigated, and the use of young animal models to evaluate
the long-term effect of morphine on nociceptive systems has
not been widely explored.
As described above, previous tests carried out by our group
demonstrated an altered nociceptive response in the tail-flick
test in animals that received morphine in the second week of
life, but it is important to further evaluate the nociception in
these animals using other nociceptive tests. To investigate the
possible mechanisms underlying this response, we selected
one of the most widely used animal models to assess the
response generated by injured tissue, which mimics some
features of post-injury pain and is thus considered to be more
relevant to clinical pain states than phasic pain, bridging the
gap between acute and chronic pain (Fig. 1) (Tjølsen et al.,
1992).
Considering the relevance of the subject, the aim of this
study was to investigate whether repeated morphine expo-
sure during early life alters the neurogenic and inflammatory
pain in the short (P16), medium (P30), and long term (P60)
using the formalin test, as well as to investigate the possible
mechanisms involved in these changes.2. Results
2.1. Short-, medium-, and long-term effects of repeated
morphine administration on the nociceptive behavior induced by
formalin
After daily morphine exposure, from P8 to P14, the nociceptive
behaviors were compared between the control and morphine
groups at P16, P30, and P60. The subcutaneous injection of 2%formalin into the plantar region of the hindpaw of animals of
all ages and in all groups resulted in behavioral responses,
such as biphasic licking, biting, and flicking of the injected
paw. At P16, 2 days after the end of repeated morphine
exposure, there were no differences between the groups of
animals for either phase (phase I: F=0.69; phase II: F=0.05,
Student's t-test, P>0.05 for both phases; Fig. 2A). At P30, the
morphine group showed a stronger nociceptive response in
phase II (phase I: F=1.16, Student's t-test, P>0.05; phase II:
F=1.21, Student's t-test, P<0.05; Fig. 2B). At P60, the morphine
group showed a stronger nociceptive response in both phases
of the formalin test (phase I: F=0.018; phase II: F=0.035,
Student's t-test, P<0.05 for both phases; Fig. 2C).
2.2. Effects of indomethacin administration on behavior in
the formalin test at P30 and P60 after repeated morphine
administration
After dailymorphine exposure, fromP8 to P14, we investigated
whether an injection of indomethacin 30 min before the
formalin test was able to reverse the increased nociceptive
behavior at P30 and P60 in the morphine group compared to
the control group. Our results demonstrated that at P30 the
control-indomethacin (C-Indomethacin) and morphine-indo-
methacin (M-indomethacin) animals experienced a decrease
in the nociceptive response in both phases of the test when
compared to control-vehicle I (C-vehicle I) and morphine-
vehicle I (M-vehicle I) (phase I: F=29.0, phase II: F=22.65,
one-way ANOVA, Bonferroni's test, P<0.05 for both phases;
Fig. 3A). However, the morphine-indomethacin group pre-
sented a more intense nociceptive response when compared
to control-indomethacin in both phases of the test (one-way
ANOVA, Bonferroni's test, P<0.05; Fig. 3A). The morphine-
vehicle I group showed no difference in the nociceptive
response compared to the control-vehicle I group in phase I
(one-way ANOVA, P>0.05), but it presented a more intense
nociceptive response in phase II when compared to all groups
(one-way ANOVA/Bonferroni's test P<0.05, Fig. 3A).
At P60, we observed a pattern of nociceptive behavior
similar to the responses recorded at P30 for all groups in both
phases (phase I: F=6.4, phase II: F=12.52, one-way ANOVA,
Bonferroni's test, P>0.05, Fig. 3B). However, the morphine-
Fig. 2 – Changes in the formalin-induced neurogenic and
inflammatory pain after repeated morphine administration in
early life: (A) at P16, 2 days after termination of repeated
morphine exposure, the animals did not show differences
between groups in either phase (Student'st-test, P>0.05); (B) at
P30, the animals did not showdifferences between the groups
in phase I (Student's t-test, P>0.05), but during phase II, they
presented a significant difference (Student's t test, P<0.05);
(C) at P60, there was a significant difference between the
animals in both phases of the formalin test (Student's t-test,
P<0.05, panel C). #Significant difference from control group.
Fig. 3 – Effects of indomethacin administration 30 min before
the formalin test at P30 and P60 after repeated morphine
administration inearly life: (A) atP30 the control-indomethacin
andmorphine-indomethacingroupsweresignificantlydifferent
from all groups in phase I (one-way ANOVA/Bonferroni's test,
P<0.05); at phase II, all groups were significantly different from
eachother (one-wayANOVA/Bonferroni's testP<0.05). (B) at P60,
all groups were significantly different from each other in both
phases of the test (one-way ANOVA/Bonferroni's test, P<0.05).
#Significant difference from control-vehicle I group; **significant
difference between groups.
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in phases I and II when compared to other groups (one-way
ANOVA/Bonferroni's test, P<0.05, Fig. 3B).2.3. Effects of ketamine administration on the formalin test
at P30 and P60 after repeated morphine administration
The administration of ketamine 30 min before the formalin
test prevented the higher nociceptive response observed in
themorphine group compared to the control group, at P30 and
P60. Our results show that at P30, the control-ketamine
(C-ketamine) and morphine-ketamine (M-ketamine) groups
presented decreased nociceptive responses in both phases of
the test when compared to the control-vehicle II (C-vehicle II)
and morphine-vehicle II (M-vehicle II) groups (phase I: F=7.97,
phase II: F=79.28, one-way ANOVA, Bonferroni's test, P<0.05
for both phases; Fig. 4A). However, the morphine-ketamine
group exhibited a less marked nociceptive response when
compared to the control-ketamine group in both phases of the
test (one-way ANOVA, Bonferroni's test, P<0.05; Fig. 4A). The
morphine-vehicle II group, in turn, presented a similar
nociceptive response to that of the control-vehicle II group
in phase I (one-way ANOVA, P>0.05), but a higher nociceptive
Fig. 4 – Effects of ketamine administration 30 min before the
formalin test at P30 and P60 after repeated morphine
administration in early life: (A) at P30, the control-ketamine
and morphine-ketamine groups were similar, but they were
significantly different from other groups (control-vehicle II
and morphine-vehicle II) in phase I (one-way ANOVA/
Bonferroni's test, P<0.05). At phase II, all groups were
significantly different from each other (one-way ANOVA/
Bonferroni's test, P<0.05). (B) at P60, all groups were
significantly different from each other in both phases of the
test (one-way ANOVA/Bonferroni's test, P<0.05). #Significant
difference fromcontrol-vehicle II group; **significant difference
between groups.
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ANOVA/Bonferroni's test P<0.05, Fig. 4A).
At P60,weobserved apatternof nociceptive response similar
to that seen at P30 for all groups in both phases (one-way
ANOVA, Bonferroni's test, P<0.05, Fig. 4B). However, the
morphine-vehicle II grouppresentedamore intensenociceptive
response than all other groups in phase I and phase II (phase
I: F=5.63, phase II: F=11.92, one-way ANOVA/Bonferroni's test,
P<0.05 for both phases, Fig. 4B).3. Discussion
In this study, we demonstrated that rats that received morphine
during the secondweek of life showed an increase in nociceptive
behavior in phase II of the formalin test at P30. This increased
response was partially reversed by a non-steroidal anti-inflam-
matory drug (indomethacin) and completely reversed by anNMDA receptor antagonist (ketamine). Moreover, at P60, the
morphine-treated animals showed an increase in thenociceptive
response in both phases of the formalin test (representing the
neurogenic and inflammatory pain responses), which was also
partially reversed by indomethacin and completely reversed by
ketamine.
These results indicate that exposure to drugs in early life can
have long-lasting implications for the development of the
nervous system, such as permanent changes in pharmacolog-
ical responsesand cell signaling (for a review, see Stanwoodand
Levitt, 2004). Other investigations have uncovered the neurobi-
ological consequences of repeated opioid administration and
revealed possible neuroplastic adaptations that likely underlie
opioid-induced paradoxical pain (Vanderah et al., 2000, 2001;
Gardell et al., 2002). Thismay be a consequence of the structural
and functional immaturity of the neonatal nervous system, and
the significant changes in opioid analgesic mechanisms that
occur before and after birth (Beland and Fitzgerald, 2001; Marsh
et al., 1997; Rahman et al., 1998).
In the formalin test, the rodent hindpaw presents a
characteristic biphasic nociceptive response using both
weighted pain measures (Dubuisson and Dennis, 1977) and
continuous scoring systems (Wheeler-Aceto and Cowan,
1991). The transient early phase (occurring in the first
5–10 min) is interpreted as reflecting direct activation of
nociceptive sensory afferents by formalin, while the tonic
phase (expressed from 20 to 90 min) is regarded as depending
on an ensuing inflammatory response, associatedwith central
sensitization (Tjølsen et al., 1992; Coderre et al., 1993).
Formalin can also activate central processes that lead to
longer term events (over 3–4 weeks), such as the expression of
immediate-early genes and activation of microglia, providing
in this context a model of chronic pathological pain (Sawynok
and Liu, 2003). Thus, the increase in formalin-induced
nociceptive behavior observed in this study suggests a central
hyperexcitability of the ascending second-order dorsal horn
neurons induced by previous sustained exposure tomorphine,
and this is a long-term effect. Our results agree with those of
Zissen et al. (2006, 2007), who have demonstrated that while
infant rats (P5 to P8) are more sensitive to the long-term
changes in formalin-induced pain and mechanical thresholds
following continuous exposure to morphine, when compared
to young rats (P19 to P21), they are also better able to
compensate for changes in mechanical thresholds following
intermittent administration ofmorphine, given twice a day for
3 days. It is possible that short bouts of morphine withdrawal-
induced excitation may off-set morphine-induced inhibition
in infants, but not in young rats, and thus, may better
maintain the balance of activity and inactivity during this
crucial developmental phase.
Ossipov et al. (2005) showed that opioids can produce
hyperalgesia under many circumstances, and that such
effectsmight contribute to the drawbacks of acute and chronic
administration of these drugs. Although the mechanisms of
this phenomenon have not yet been fully clarified, research
has shown that chronic exposure to opioids induces a change
in the function of spinal cord neurons that can be manifested
as neuronal hyperactivity during opiate withdrawal (Rohde
et al., 1997; Vanderah et al., 2001; Gardell et al., 2006). Other
studies have reported that repeated opioid exposure can lead
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2001) and these adaptations may involve changes in suprasp-
inal pain modulatory circuits (Ossipov et al., 2005). Consistent
with these results, we suggest that exposure to morphine in
early life might lead to drug-induced adaptations in the
excitatory pain pathways, such as neuroplastic changes at the
receptor level and/or in the synthesis of algesic substances
(Yaksh et al., 1986), whichmay produce secondary hyperalgesic
effects that increase the intensity of the pain (Celerier et al.,
1999; Larcher et al., 1998).
The effect of ketamine seen here may be explained by
activation of the glutamatergic system in opioid-mediated
hyperalgesia (Sanford and Silverman, 2009). It is well accepted
that persistent activation of the NMDA receptor by excitatory
amino acids released from primary afferent terminals results in
the sensitization of spinal neurons (Baranauskas and Nistri,
1998), and such NMDA receptor-mediated central sensitization
is believed to drive enhanced nociception in chronic pain states
and opioid-induced abnormal pain (Larcher et al., 1998; Laulin
et al., 1999;MaoandMayer, 2001). The involvement of excitatory
neurotransmitters, mainly glutamate, in inflammatory noci-
ception is supported by the increase in levels of these
neurotransmitters in the dorsal root ganglion and dorsal horn,
elicited by chronic inflammation (Wimalawansa, 1996; Löfgren
et al., 1997; Ossipov et al., 2005). In addition, peripheral
inflammation is capable of increasing the expression of
subunits of the NMDA receptor and enhancing neurotransmit-
ter release in CNS structures related to nociception (Zhuo, 2002;
Zhao et al., 2006). Therefore, it is possible that the animals that
received morphine in early life presented central sensitization
in the medium and long term induced by changes in the
glutamatergic system, and this may be responsible, at least in
part, for the increase in nociceptive behavior in phase II of the
formalin test (which represents the inflammatory pain
response) observed in this study. This explanation for the latter
result is supportedby the fact that anNMDAreceptorantagonist
(ketamine) completely eliminated the hyperalgesia induced by
morphine exposure in early life.
In addition, indomethacin, a nonsteroidal anti-inflamma-
tory drug (NSAID), was unable to completely reverse the
hyperalgesia resulting from early morphine treatment. This
suggests that there is an inflammatory component involved,
but we cannot discard other mechanisms that may contrib-
ute to the hyperalgesia observed in this study. Following on
from previous studies that found that pre-treatment with an
NSAID may increase spinal cord levels of kynurenic acid (an
endogenous excitatory amino acid antagonist) (Edwards et
al., 2000) and partially inhibit increases in spinal cord levels
of c-fos (an immediate-early genetic marker of nociceptive
activity) stimulated by application of the rat tail ischemia–
reperfusion acute model of hyperalgesia (Lin et al., 2000),
Grace et al. (2001) reported that subcutaneous injection of
NSAIDs completely eliminated the hyperalgesic response
elicited in rats by ischemic stimulation of the tail and
suppressed the increased prostaglandin formation in the
brains of the animals. However, the relief of hyperalgesia
was short-lived and corresponded only to the first phase of
the (spontaneous) hyperalgesia (Scheuren et al., 1997). In
addition, PGE2 has been found in microdialysate of the
spinal cord after injection of formalin in the paw of the rat(Malmberg and Yaksh, 1995; Scheuren et al., 1997), and its
production was antagonized by systemic injection of para-
cetamol (Muth-Selbach et al., 1999) or by intrathecal
injection of other NSAIDs (Malmberg and Yaksh, 1992).
Direct evidence for a spinal antinociceptive action of NSAIDs
derives from observations made in patients and animal
experiments. It has been reported that intrathecal injection
of acetylsalicylic acid, salicylic acid, and indomethacin
depressed the nociceptive activity that was evoked in
thalamic neurons of rats by electrical stimulation of afferent
C-type fibers in the sural nerve (Jurna et al., 1992).
The development of nociceptive pathways is an activity-
dependent process (Fitzgerald and Jennings, 1999; Fitzgerald
and Beggs, 2001; Beggs et al., 2002), and thus, abnormal
activity such as that generated by early opioid exposure may
alter normal synaptic development producing changes in
somatosensory processing and behavior that would not
occur in similarly exposed adults. Our group has demon-
strated that neonatal rats may be more sensitive to low
doses of morphine because there is extensive re-modeling of
opioid receptor expression in the first 3 postnatal weeks
(Rahman et al., 1998; Rahman and Dickenson, 1999; Beland
and Fitzgerald, 2001). For example, at P14 spinal μ-opioid
receptors (μORs) are limited to the dorsal horn, whereas they
appear throughout the spinal grey matter at P7, and the
density of binding is seen to decrease in the first 3 postnatal
weeks, with peak binding at P7 that then falls to the adult
level by P21. This abundance of μORs in early postnatal life
could explain why exposure to morphine for 7 days, from P8
to P14, produces analgesia instead of tolerance (Rozisky et
al., 2008). Thus, the greater expression of μORs at P7 in
comparison to adult rats suggests a more widespread effect
of morphine, acting both directly within the spinal cord and
indirectly through larger termination profiles of primary
afferents (Nandi et al., 2004). This, coupled with the over-
expression of excitatory amino acid receptors, at the primary
afferent-spinal cord synapse, supports a potential role for
μORs in the normal maturation of nociceptive circuitry, and
hence, disruption of this by exogenous administration of
opioid agonists may have detrimental consequences for the
maturation of pain circuitry (Thornton and Smith, 1998;
Thornton et al., 2000). Activity-dependent processes drive
the maturation of nociceptive C-fibers during this period of
neurodevelopment (Beggs et al., 2002; Fitzgerald et al., 1994).
In adult rats, Aδ and C but not Aβ primary afferent fibers
transmit painful stimuli. In contrast, in P7 rats Aβ primary
afferents can also transmit such stimuli (Fitzgerald and
Jennings, 1999). It has been hypothesized that increased
activity in Aβ-fibers early in development may be modulated
by sub-threshold C-fiber depolarization that primes the spinal
cord for Aβ-fiber input (Dickenson and Rahman, 1999). Func-
tionally, in adult rodents opioid agonists selectively inhibit Aδ-
andC-fiber nociceptors but not Aβ-fibers (Dickenson et al., 1987;
Rahman and Dickenson, 1999). In contrast, in young rats
morphine can inhibit Aβ- and C-fiber-mediated activity in the
lumbar spinal cord (Rahman et al., 1998), which parallels
expression of μORs in both small (Aδ and C) and large (Aβ)
diameter cell bodies in the dorsal root ganglion. Based on the
results of our study, we suggest that at P16 the animals do not
exhibit increased nociceptive behavior in the formalin test
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development of C-fibers during maturation. However, we did
observe that following the formalin test, the treated animals
presented an inflammation-like edema in the formalin-injected
hindpaw, which wasmeasured and compared to the volume of
the non-injected hindpaw by plethysmometry. It is interesting
to note that there were no differences between the volume of
formalin-injectedhindpaws in themorphineandcontrol groups
(data not shown).
Taking into account the importance of a deeper under-
standing of the effects throughout life of opioid analgesia at
birth, and that previous results from our group showed that
morphine exposure in early life lead to changes in the
analgesic response in adult life (Rozisky et al., 2008), we
hypothesized that the use of opioids in early life can induce
persistent changes in nociceptive and opioid analgesic
responses. We conclude from the present results that the
altered nociceptive response induced by repeated morphine
exposure can change in an age-dependent manner. In
addition, the altered nociceptive response was expressed
until adulthood, and this effect was partially reversed by
indomethacin and completely reversed by an NMDA receptor
antagonist. However, it should be noted that the response is
complex and unlikely to be predominantly caused by any
single mediator. Taken together, our data indicate that
opioids elicit glutamatergic adaptations at the system level.
Finally, the behavioral changes seen in response to repeated
exposure to morphine during early life illustrate the need to
examine nociceptive processing in neonatal patients who
have been exposed to therapeutic morphine; moreover, this
indicates the importance of evaluating the clinical conse-
quences of long-term opioid administration. These findings
also highlight the need for further studies involving the
design of pharmacological approaches that may counteract
opioid-induced neuroadaptations and subsequently prevent
abnormal pain states.4. Experimental procedures
4.1. Animals
Eight-day-old male Wistar rats were divided into two groups:
saline-control (C) and morphine-treated (M). Naive animals were
housed in home cages made of Plexiglas (65 cm×25 cm×15 cm)
with sawdust covering the floor. Animals were maintained on a
standard 12-h dark/light cycle (lights on between 0700 h and
1900 h) at room temperature (22±2 °C). The animals had free
access to food andwater. At birth, the litters were standardized to
contain up to 8 pups per dam, and the pups remained with their
mothers until 21 days of age. Rats at P8 were chosen because it
is accepted that animals of this age are at a similar stage
of neurological development to that of a human newborn
(Fitzgerald and Anand, 1993). It is also accepted that they are in a
physiologically immature state (Pattinson and Fitzgerald, 2004)
since thisperiod ischaracterizedbymajordevelopmental changes
in the brain and plasticity of the developing pain system (Bishop,
1982; Kim et al., 1996; Rabinowicz et al., 1996). Animal handling
and all experiments were performed in accordance with interna-tional guidelines for animal welfare. The protocol of this
experimental study was approved by the Ethics Committee of
the institution where the work was conducted.
4.2. Pharmacological treatment
Each animal received saline (control group) ormorphine (5 μg s.c.
in the mid-scapular area; morphine group) starting at P8, then
once a day for 7 days. This dose had been chosen based on a
previous study by Rozisky et al. (2008, 2010), and it produced
analgesia in all animals submitted to the tail-flick test. All
treatments were administered at the same time each day
(1100 h). One milliliter of morphine sulphate (Dimorf® 10mg/
ml, obtained from Cristália, Porto Alegre, Rio Grande do Sul,
Brazil) was diluted in 9ml of 0.9%NaCl (saline). The formalin test
was performed in 16-, 30-, and 60-day-old rats (Fig. 1). The
number of animals used per group was 8 to 15.
At the ages where we observed significant differences in the
nociceptive behavior in the formalin test, the control and
morphine groups were subdivided into four groups, each one
designed to evaluate the effect of i.p. administration of an
NMDA receptor antagonist or non-steroidal anti-inflammatory
drug (NSAID), applied 30 min before the formalin test: (1) non-
steroidal anti-inflammatory drug: 10mg/kg of indomethacin
(Indomethacin®, obtained from Sigma-Aldrich, São Paulo,
Brazil) (Bastos et al., 2004) diluted in 1.29% sodium bicarbonate
solution (control-indomethacin, morphine-indomethacin);
(2) vehicle for indomethacin (vehicle I): 10 mg/kg of 1.29%
sodium bicarbonate solution (pH=7.4) (control-vehicle I, mor-
phine-vehicle I); (3) NMDA receptor antagonist: 30 mg/kg of
ketamine (Cetamine®, obtained from Hospital de Clínicas de
Porto Alegre, Brazil) (Campos et al., 2006) diluted in 0.9% saline
(control-ketamine, morphine-ketamine); (4) vehicle for
ketamine (vehicle II): 30 mg/kg of saline (control-vehicle II,
morphine-vehicle II) (Fig. 1). The number of animals used per
group was 6 to 9.4.3. Formalin test
The formalin testwas performed as previously described (Tjølsen
etal., 1992; Tai et al., 2006)withminormodifications. Twenty-four
hours before the test, each animal was placed in the chamber for
10min to familiarize themwith the procedure, since the novelty
of the apparatus itself can induce antinociception (Netto et al.,
2004). The animalswere injected s.c. on the plantar surface of the
left hindpaw with 0.17ml/kg of a 2% formalin solution (Formal-
dehyde P.A.®, obtained from Sigma-Aldrich, São Paulo, Brazil)
diluted in 0.9% NaCl (saline). Each animal was observed in a
varnished wood cage, measuring 60×40×50 cm, with the inside
linedwith glass, and the nociceptive response was recorded for a
period of 30min. This test produces two distinct phases of
nociceptive behavior: an early, transient phase (phase I; up to
5minafter the injection) anda late, persistentphase (phase II; 15–
30min after the injection). Phase I has been considered to reflect
direct stimulation of primary afferent fibers, predominantly
C-fibers (neurogenic pain) (Martindale et al., 2001), whereas
phase II is dependent on peripheral inflammation (inflammatory
pain) (Dubuisson and Dennis, 1977; Shibata et al., 1998; Tjølsen et
al., 1992). The total time (seconds) spent in licking, biting, and
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I and II. The test was performed once only in each rat.4.4. Statistical analysis
Data were expressed as means±standard error of the mean
(SEM). Depending on the experiment, Student's t-test or one-
way ANOVA was performed, followed by a multiple compar-
isons test (Bonferroni's test) when indicated. Differences were
considered statistically significant if P<0.05.Acknowledgments
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